---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-21-009384"
form_type: "8-K"
ticker: "AGTX"
cik: "0001603345"
company_name: "Agentix Corp."
filed_at: "2021-12-21T23:59:59+00:00"
generated_at: "2026-06-27T23:20:15.956387+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agentix and RTI announce worldwide exclusive license for NAFLD, NASH, T2D, obesity candidates

## Summary
- License covers RTI small-molecule candidates for NAFLD, NASH, T2D, and obesity.
- Agentix must complete Phase I trials by Jan 15, 2023; Phase II by Oct 2025; Phase III by Oct 2028.
- Agentix plans to file IND with FDA in ~12 months; RTI to assist with IND-enabling toxicology and GMP manufacturing.
- No financial terms disclosed; pre-clinical data show efficacy in animal models of metabolic diseases.

## SEC filing metadata
- accession: 0001477932-21-009384
- form_type: 8-K
- ticker: AGTX
- cik: 0001603345
- company_name: Agentix Corp.
- filed_at: 2021-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603345/000147793221009384/0001477932-21-009384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603345/000147793221009384/agtx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-21-009384
- JSON: https://secwatch.observer/filing/0001477932-21-009384.json
- Plain text: https://secwatch.observer/filing/0001477932-21-009384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.